Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $178.71.

A number of research firms have issued reports on SRPT. Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Finally, UBS Group upped their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th.

Sarepta Therapeutics Trading Up 0.3 %

Shares of SRPT stock opened at $121.59 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a fifty-two week low of $91.34 and a fifty-two week high of $173.25. The company has a market cap of $11.61 billion, a PE ratio of 97.27 and a beta of 0.77. The stock’s fifty day moving average price is $122.85 and its two-hundred day moving average price is $131.49.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Sunbelt Securities Inc. increased its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank increased its stake in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC acquired a new position in Sarepta Therapeutics during the second quarter worth $43,000. UMB Bank n.a. lifted its stake in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at about $59,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.